DEP milestone triggers partner option fee
Filed with ASX · · 2 pages · English
Summary by 6ix AI
This milestone indicates a tangible commercial outcome and moves the program into an option period for Radiopharm to potentially license Starpharma's DEP® technology. If Radiopharm exercises this option, Starpharma could receive substantial payments and royalties, validating the DEP® platform's potential in radiopharmaceutical development. The CEO of Starpharma highlighted the collaboration's importance and the potential for future financial benefits during the option period.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Starpharma Holdings Limited on 6ix
Earlier from Starpharma
- Positive DEP HER2-Lu preclinical data support Phase 1 entry
- DEP radiopharmaceutical data supports patent application
- FDA confirms path to DEP HER2 first-in-human study
- Half Yearly Report and Accounts
- Quarterly Activities/Appendix 4C Cash Flow Report
Later from Starpharma
- Quarterly Activities Report and Appendix 4C
- Fully Underwritten Entitlement Offer to Raise $32 Million
- Entitlement Offer Investor Presentation
- Successful Completion of $32 million Entitlement Offer
- Preliminary Final Report
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma